Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Last Patient enrolled recovers in 10 days, great news

<< Previous

Bullboard Posts

Next >>

Comment by talisman47on Dec 25, 2020 2:49pm

260 Views

Post# 32182825

RE:RE:RE:RE:Last Patient enrolled recovers in 10 days, great news

Could be as you say, however, I don't think that if a patient completes a 15 day trial period that it means they went home after it. The trial was just to collect information for 15 days, the patient may have been well enough to get out of ICU, or they may have had to continue to stay in ICU after the Algernon 15 day trial completed with them. If a patient got out of ICU 4-5 days faster I would think the information woud have said that. Hope your right....

Enjoy the holidays !

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features